D James Surmeier1, Jack T Nguyen2, Nicola Lancki3, Charles S Venuto4, David Oakes5, Tanya Simuni6, Richard K Wyse7. 1. Department of Neuroscience, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA. 2. Cavalon Therapeutics, Berkeley, California, USA. 3. Biostatistics Collaboration Center, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA. 4. Department of Neurology, Center for Health and Technology, University of Rochester, Rochester, New York, USA. 5. Department of Biostatistics and Computational Biology, University of Rochester, Rochester, New York, USA. 6. Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA. 7. Cure Parkinsons, London, United Kingdom.
Abstract
BACKGROUND: Recent examination of the STEADY-PD III isradipine clinical trial data concluded that early-stage Parkinson's disease (PD) participants who had longer exposure to isradipine had a significant delay in their need for symptomatic medication, as well as a lower medication burden at the end of the trial. These findings suggest that greater exposure to isradipine might slow disease progression. OBJECTIVES: To test this hypothesis, the data from the STEADY-PD II isradipine clinical trial, in which an extended-release (ER) formulation of the drug was used, was re-examined. METHODS: The re-analysis of the STEADY-PD II data was restricted to participants assigned placebo or tolerable isradipine treatment (10 mg isradipine/day or less). The effect of isradipine treatment was assessed by Unified Parkinson's Disease Rating Scale (UPDRS) at the end of the 52-week trial, rather than by last observation carried forward at the beginning of symptomatic therapy. RESULTS: Participant cohorts were well-matched for baseline disability, initial disease progression, and time to initiation of symptomatic therapy. Participants given 10 mg/day ER isradipine had significantly smaller total and part 3 UPDRS scores at the end of the trial than did the placebo cohort. Post hoc adjustment for symptomatic therapy diminished the statistical significance of these differences. In those participants not taking a monoamine oxidase B inhibitor, the progression in UPDRS scores also was significantly reduced. CONCLUSIONS: These results are consistent with the recent secondary analysis of the STEADY-PD III clinical trial-suggesting that clinically attainable brain exposure to isradipine may slow early-stage PD progression.
BACKGROUND: Recent examination of the STEADY-PD III isradipine clinical trial data concluded that early-stage Parkinson's disease (PD) participants who had longer exposure to isradipine had a significant delay in their need for symptomatic medication, as well as a lower medication burden at the end of the trial. These findings suggest that greater exposure to isradipine might slow disease progression. OBJECTIVES: To test this hypothesis, the data from the STEADY-PD II isradipine clinical trial, in which an extended-release (ER) formulation of the drug was used, was re-examined. METHODS: The re-analysis of the STEADY-PD II data was restricted to participants assigned placebo or tolerable isradipine treatment (10 mg isradipine/day or less). The effect of isradipine treatment was assessed by Unified Parkinson's Disease Rating Scale (UPDRS) at the end of the 52-week trial, rather than by last observation carried forward at the beginning of symptomatic therapy. RESULTS: Participant cohorts were well-matched for baseline disability, initial disease progression, and time to initiation of symptomatic therapy. Participants given 10 mg/day ER isradipine had significantly smaller total and part 3 UPDRS scores at the end of the trial than did the placebo cohort. Post hoc adjustment for symptomatic therapy diminished the statistical significance of these differences. In those participants not taking a monoamine oxidase B inhibitor, the progression in UPDRS scores also was significantly reduced. CONCLUSIONS: These results are consistent with the recent secondary analysis of the STEADY-PD III clinical trial-suggesting that clinically attainable brain exposure to isradipine may slow early-stage PD progression.
Authors: J A Obeso; M Stamelou; C G Goetz; W Poewe; A E Lang; D Weintraub; D Burn; G M Halliday; E Bezard; S Przedborski; S Lehericy; D J Brooks; J C Rothwell; M Hallett; M R DeLong; C Marras; C M Tanner; G W Ross; J W Langston; C Klein; V Bonifati; J Jankovic; A M Lozano; G Deuschl; H Bergman; E Tolosa; M Rodriguez-Violante; S Fahn; R B Postuma; D Berg; K Marek; D G Standaert; D J Surmeier; C W Olanow; J H Kordower; P Calabresi; A H V Schapira; A J Stoessl Journal: Mov Disord Date: 2017-09 Impact factor: 10.338
Authors: M P McDermott; J Jankovic; J Carter; S Fahn; S Gauthier; C G Goetz; L I Golbe; W Koller; A E Lang; C W Olanow Journal: Arch Neurol Date: 1995-06
Authors: Tanya Simuni; Jeffrey D Long; Chelsea Caspell-Garcia; Christopher S Coffey; Shirley Lasch; Caroline M Tanner; Danna Jennings; Karl D Kieburtz; Kenneth Marek Journal: Ann Clin Transl Neurol Date: 2016-05-17 Impact factor: 4.511
Authors: Steven M Graves; Zhong Xie; Kristen A Stout; Enrico Zampese; Lena F Burbulla; Jean C Shih; Jyothisri Kondapalli; Tommaso Patriarchi; Lin Tian; Lars Brichta; Paul Greengard; Dimitri Krainc; Paul T Schumacker; D James Surmeier Journal: Nat Neurosci Date: 2019-12-16 Impact factor: 24.884
Authors: Charles S Venuto; Luoying Yang; Monica Javidnia; David Oakes; D James Surmeier; Tanya Simuni Journal: Ann Clin Transl Neurol Date: 2021-01-18 Impact factor: 4.511
Authors: Enrico Zampese; David L Wokosin; Patricia Gonzalez-Rodriguez; Jaime N Guzman; Tatiana Tkatch; Jyothisri Kondapalli; William C Surmeier; Karis B D'Alessandro; Diego De Stefani; Rosario Rizzuto; Masamitsu Iino; Jeffery D Molkentin; Navdeep S Chandel; Paul T Schumacker; D James Surmeier Journal: Sci Adv Date: 2022-09-30 Impact factor: 14.957